Teijo Pellinen
Overview
Explore the profile of Teijo Pellinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Luomala L, Mattila K, Vainio P, Nisen H, Pellinen T, Lohi J, et al.
Cancer Med
. 2024 Feb;
13(3):e6998.
PMID: 38400673
Background: Hypoxia inducible factors, HIF-1α and HIF-2α, and their main regulators, the prolyl hydroxylase domain proteins (PHDs), mediate cellular response to hypoxia and contribute to tumor progression in clear cell...
12.
Piki E, Dini A, Raivola J, Salokas K, Zhang K, Varjosalo M, et al.
Cell Death Discov
. 2023 Jul;
9(1):222.
PMID: 37400436
Wnt pathway dysregulation through genetic and non-genetic alterations occurs in multiple cancers, including ovarian cancer (OC). The aberrant expression of the non-canonical Wnt signaling receptor ROR1 is thought to contribute...
13.
Jungen S, Noti L, Christe L, Galvan J, Zlobec I, Muller M, et al.
Front Med (Lausanne)
. 2023 Apr;
10:1110529.
PMID: 37035329
Introduction: Over the years, the molecular classification of endometrial carcinoma has evolved significantly. Both POLEmut and MMRdef cases share tumor biological similarities like high tumor mutational burden and induce strong...
14.
Ollila-Raj H, Murumagi A, Pellinen T, Arjama M, Sutinen E, Volmonen K, et al.
Lung Cancer
. 2023 Mar;
178:213-219.
PMID: 36878102
Objectives: Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment options. The first-line therapy has remained unchanged for two decades and consists of pemetrexed in combination with cisplatin. Immune-checkpoint...
15.
Pellinen T, Sandeman K, Blom S, Turkki R, Hemmes A, Valimaki K, et al.
Cancer Res Commun
. 2023 Mar;
2(3):172-181.
PMID: 36874403
Significance: These findings may have a significant impact on clinical decision making as more radical treatments may be recommended for men with a combination of MRI-visible primary tumors and FAP...
16.
Murumagi A, Ungureanu D, Khan S, Arjama M, Valimaki K, Ianevski A, et al.
Br J Cancer
. 2022 Dec;
128(4):678-690.
PMID: 36476658
Many efforts are underway to develop novel therapies against the aggressive high-grade serous ovarian cancers (HGSOCs), while our understanding of treatment options for low-grade (LGSOC) or mucinous (MUCOC) of ovarian...
17.
Pellinen T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, Strell C, Mezheyeuski A, et al.
J Natl Cancer Inst
. 2022 Sep;
115(1):71-82.
PMID: 36083003
Background: Cancer-associated fibroblasts (CAFs) are molecularly heterogeneous mesenchymal cells that interact with malignant cells and immune cells and confer anti- and protumorigenic functions. Prior in situ profiling studies of human...
18.
Ollila H, Mayranpaa M, Paavolainen L, Paajanen J, Valimaki K, Sutinen E, et al.
Front Oncol
. 2022 Jul;
12:870352.
PMID: 35795056
Background: Pleural mesothelioma (MPM) is an aggressive malignancy with an average patient survival of only 10 months. Interestingly, about 5%-10% of the patients survive remarkably longer. Prior studies have suggested...
19.
Karihtala K, Leivonen S, Karjalainen-Lindsberg M, Chan F, Steidl C, Pellinen T, et al.
Blood Adv
. 2021 Dec;
6(6):1919-1931.
PMID: 34941990
Emerging evidence indicates a major impact for the tumor microenvironment (TME) and immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma (cHL). We used gene expression profiling...
20.
Autio M, Leivonen S, Bruck O, Karjalainen-Lindsberg M, Pellinen T, Leppa S
Clin Cancer Res
. 2021 Dec;
28(4):781-792.
PMID: 34907083
Purpose: Tumor-infiltrating immune cells have prognostic significance and are attractive therapeutic targets. Yet, the clinical significance of their spatial organization and phenotype in diffuse large B-cell lymphoma (DLBCL) is unclear....